IGF::OT::IGF IGF CORE INFRASTRUCTURE SUPPORT

IGF::OT::IGF IGF 核心基础设施支持

• 批准号: 9162606
• 负责人: PAUL J LIMBURG
• 金额: $ 79.77万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-24 至 2016-09-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9162606
• 关键词: Chemoprevention; Clinical; Clinical Trials; Conduct Clinical Trials; Contractor; Data; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; Laboratories; Maintenance; Malignant Neoplasms; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; Preventive; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; cancer prevention; clinically relevant; data management; interest; meetings; prevention clinical trial; programs; protocol development

The National Cancer Institute (NCI), Division of Cancer Prevention (DCP) Phase 0/I/II Cancer Prevention Clinical Trials Program supports early clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents of interest to DCP. The agents to be studied shall include agents developed by the pharmaceutical industry and provided to DCP for collaborative development, commercially available agents, and agents developed by DCP. The objectives of this Task Order are to provide the core infrastructure to support the conduct of the clinical trials.

美国国家癌症研究所（NCI）癌症预防部（DCP）0/I/II期癌症预防临床试验计划支持早期临床试验，以快速评估DCP感兴趣的癌症预防剂的临床活性和生物学效应。 待研究的制剂应包括由制药行业开发并提供给DCP进行合作开发的制剂、市售制剂和DCP开发的制剂。 本任务指令的目的是提供支持临床试验开展的核心基础设施。